title: How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results
source: Yahoo
date: 2025-10-06
url: https://finnhub.io/api/news?id=f3f2086007ac91191096aa6bdac656413082b1bbea04982fe6d38045151d30d0
JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.
